共查询到20条相似文献,搜索用时 31 毫秒
1.
Comparison of abluminal biodegradable polymer biolimus‐eluting stents and durable polymer everolimus‐eluting stents in the treatment of coronary bifurcations 下载免费PDF全文
Charis Costopoulos MD Azeem Latib MD Toru Naganuma MD Alessandro Sticchi MD Santo Ferrarello MD Damiano Regazzoli MD Alaide Chieffo MD Filippo Figini MD Mauro Carlino MD Matteo Montorfano MD Charbel Naim MD Masanori Kawaguchi MD Argyrios Gerasimou MD Francesco Giannini MD Cosmo Godino MD Antonio Colombo MD 《Catheterization and cardiovascular interventions》2014,83(6):889-895
2.
3.
Two‐year clinical outcomes of the NOBORI biolimus‐eluting stents versus XIENCE/PROMUS everolimus‐eluting stents in small vessel disease 下载免费PDF全文
Hiroyuki Jinnouchi MD Shoichi Kuramitsu MD Tomohiro Shinozaki MPH Takashi Hiromasa MD Yohei Kobayashi MD Takashi Morinaga MD Kyohei Yamaji MD Yoshimitsu Soga MD Shinichi Shirai MD Kenji Ando MD 《Catheterization and cardiovascular interventions》2016,88(5):E132-E138
4.
5.
Long‐term safety and efficacy of second‐generation everolimus‐eluting stents compared to other limus‐eluting stents and bare metal stents in patients with acute coronary syndrome 下载免费PDF全文
Alfazir Omar MBChB Rebecca Torguson MPH Hironori Kitabata MD PhD Lakshmana K. Pendyala MD Joshua P. Loh MBBS Marco A. Magalhaes MD Lowell F. Satler MD William O. Suddath MD Augusto D. Pichard MD Ron Waksman MD 《Catheterization and cardiovascular interventions》2014,84(7):1053-1060
6.
Juan A. Herrador MD Juan C. Fernandez MD Manuel Guzman MD Victor Aragon MD 《Catheterization and cardiovascular interventions》2011,78(7):1086-1092
Objectives : To compare zotarolimus‐eluting stent (Endeavor Sprint®; ZES‐S) and the everolimus‐eluting stent (Xience V®; EES) in the treatment of coronary bifurcation lesions Background : Both these stents have demonstrated good outcomes in the treatment of coronary lesions. However, the outcomes with respect to treatment of bifurcation lesions have yet to be conclusively demonstrated. Methods : In this single centered, nonrandomized, open label study, we treated, between August 2006 and December 2008, 110 bifurcations with ZES‐S and, in a second stage of the study, 129 bifurcations with EES. The primary end point was to compare the rate of major adverse cardiac events (MACE) (death, myocardial infarction, and new target lesion revascularization) in‐hospital and at 12 months of follow‐up. Provisional T stenting was the strategy used in the majority of cases. Angiographic follow‐up was performed only in patients who presented signs or symptoms suggestive of angina or ischemia. Results : There were no significant differences in in‐hospital MACE between the groups (ZES‐S: 8.1%; EES: 6.2%; P = 0.5). At 12 months, the ZES‐S group had significantly more MACE than the EES group (23.1% vs. 4.5%; P < 0.001) and an elevated index of new revascularization of the bifurcation (17.5% vs. 3.2%; P < 0.001). There were no significant differences in mortality (four patients in ZES‐S vs. one in EES; P = 0.14). Conclusion : The treatment of coronary bifurcation lesions using everolimus‐eluting stents results in better outcomes at 12 months of follow‐up than zotarolimus‐eluting stents. © 2011 Wiley Periodicals, Inc. 相似文献
7.
Francisco Javier Toledano Delgado MD Manuel Pan Álvarez‐Ossorio MD José Suárez de Lezo Cruz‐Conde MD Francisco Mazuelos Bellido MD Miguel Ángel Romero Moreno MD Alfonso Medina Fernández‐Aceytuno MD Javier Suárez de Lezo Herrerosde Tejada MD Soledad Ojeda Pineda MD José María Segura Saint‐Gerons MD Djordje Pavlovic MD 《Catheterization and cardiovascular interventions》2014,84(5):720-726
8.
9.
Rationale and study design of the RESERVOIR trial: A randomized trial comparing reservoir‐based polymer‐free amphilimus‐eluting stents versus everolimus‐eluting stents with durable polymer in patients with diabetes mellitus 下载免费PDF全文
R. Romaguera MD S. Brugaletta MD PhD J. Gomez‐Lara MD PhD E. Pinar MD P. Jiménez‐Quevedo MD M. Gracida MD G. Roura MD J.L. Ferreiro MD L. Teruel MD J.A. Gómez‐Hospital MD PhD E. Montanya MD F. Alfonso MD M. Valgimigli MD M. Sabate MD PhD A. Cequier MD PhD 《Catheterization and cardiovascular interventions》2015,85(4):E116-E122
10.
11.
12.
Sebastian Kufner Steffen Massberg Michael Dommasch Robert A. Byrne Klaus Tiroch Sabine Ranftl Massimiliano Fusaro Albert Schmig Adnan Kastrati Julinda Mehilli 《Catheterization and cardiovascular interventions》2011,78(2):161-166
Background : In the Intracoronary Stenting and Angiographic Results: Test Efficacy of 3 Limus‐Eluting Stents (ISAR‐TEST‐4) trial, we demonstrated the noninferiority of biodegradable polymer (BP) sirolimus‐eluting stent to permanent polymer (PP) sirolimus/everolimus‐eluting stent (Cypher/Xience‐V) on the basis of clinical outcomes. In this study, we compare the antirestenotic efficacy of these stents in ISAR‐TEST‐4 patients with paired angiographic studies. Methods : Patients with de novo coronary lesions in native vessels (excluding left main lesions) were randomly assigned to receive a BP stent or a PP stent. Endpoints of interest of this study were in‐stent late lumen loss, in‐segment binary restenosis, and restenosis morphology at 6–8‐month follow‐up angiogram. Results : Of the 2,603 patients (3,372 lesions) enrolled in ISAR TEST‐4 trial, 2,016 patients (2,637 lesions) underwent repeat angiographic examination 6–8 months after randomization: 1,006 patients (1,323 lesions) treated with BP stents and 1,010 patients (1,314 lesions) treated with PP stents. No difference was observed between BP and PP stents in in‐stent late lumen loss (0.24 ± 0.6 vs. 0.26 ± 0.5 mm, respectively, P = 0.49) or in in‐segment binary restenosis (11.6% [153 lesions] vs. 11.8% [155 lesions], P = 0.85). Focal pattern of restenosis was observed in the majority of patients receiving either BP or PP stents. The diffuse pattern of restenosis was observed in 26.8% of patients treated with BP stent and 26.5% of patients treated with PP stent (P = 0.79). Conclusion : Angiographic characteristics of restenosis after BP‐based limus‐eluting stents are similar to those of PP‐based limus‐eluting stents. © 2011 Wiley‐Liss, Inc. 相似文献
13.
14.
15.
16.
Procedural resources utilization and clinical outcomes with bioresorbable everolimus‐eluting scaffolds and Pt‐Cr everolimus‐eluting stent with resorbable abluminal polymer in clinical practice. A randomized trial 下载免费PDF全文
Jose M. de la Torre Hernandez MD PhD Tamara Garcia Camarero MD Dae‐Hyun Lee MD Fermin Sainz Laso MD Gabriela Veiga Fernandez MD Tania Pino MD Silvia Rubio MD Pablo Legarra MD Jorge R. Valdivia MD Javier Zueco Gil MD 《Catheterization and cardiovascular interventions》2017,90(2):E25-E30
17.
Safety and efficacy profile of bioresorbable‐polylactide‐polymer‐biolimus‐A9‐eluting stents versus durable‐polymer‐everolimus‐ and zotarolimus‐eluting stents in patients with acute coronary syndrome 下载免费PDF全文
Milosz Jaguszewski MD PhD Manuela Dörig Antonio H. Frangieh MD Jelena‐Rima Ghadri MD Victoria Lucia Cammann Johanna Diekmann L. Christian Napp MD Fabrizio D'Ascenzo MD Yoichi Imori MD Slayman Obeid MD Willibald Maier MD Thomas F. Lüscher MD Christian Templin MD PhD 《Catheterization and cardiovascular interventions》2016,88(6):E173-E182
18.
Comparison of 2‐year outcomes between zotarolimus‐eluting and everolimus‐eluting new‐generation cobalt–chromium alloy stents in real‐world diabetic patients 下载免费PDF全文
Tadashi Miyazaki MD Azeem Latib MD Vasileios F. Panoulas MD PhD MRCP Sakiko Miyazaki MD PhD MPH Charis Costopoulos MD Katsumasa Sato MD Toru Naganuma MD Hiroyoshi Kawamoto MD Hiroyuki Daida MD PhD Antonio Colombo MD 《Catheterization and cardiovascular interventions》2015,86(1):E11-E18
Background : To date, it remains unknown whether different types of new‐generation drug‐eluting stents have a differential impact on long‐term outcomes in diabetic patients. Methods and Results : In this historical cohort study (two Italian centers), we analyzed 400 diabetic patients with 553 coronary lesions treated with new‐generation CoCr zotarolimus‐eluting stents (R‐ZES: 136 patients, 196 lesions) or everolimus‐eluting stents (EES: 264 patients, 357 lesions) between October 2006 and August 2012. Primary endpoint was the occurrence of major adverse cardiac events (MACE) over a 2‐year follow‐up period. MACE was defined as all‐cause mortality, any myocardial infarction (MI) and/or target lesion revascularization (TLR). Multivessel revascularization, intervention for restenotic lesion and use of intravascular ultrasound were significantly higher in the R‐ZES group, whereas small stent (≤2.5 mm) deployment was significantly higher in the EES group. At 2‐year follow‐up, there was no significant difference in occurrence of MACE (R‐ZES vs EES: 22.8% vs 18.9%, P = 0.39). Similarly, no significant differences were observed in the composite endpoint of all‐cause mortality/MI (10.0% vs 10.3%, P = 0.86) or TLR (12.4% vs 7.4%, P = 0.11). Adjustment for confounders and baseline propensity‐score matching did not alter the aforementioned associations. Conclusion : After 2 years of follow up similar outcomes (MACE, all‐cause mortality/MI, TLR) were observed in real‐world diabetic patients, including those with complex lesions and patient characteristics, treated with R‐ZES and EES. © 2015 Wiley Periodicals, Inc. 相似文献
19.
Clinical outcomes of real‐world patients treated with an amphilimus polymer‐free stent versus new generation everolimus‐eluting stents 下载免费PDF全文
Vasileios F. Panoulas MD PhD Azeem Latib MD Charbel Naim MD Katsumasa Sato MD Alfonso Ielasi MD Maurizio Tespili MD Cosmo Godino MD Luca Testa MD Francesco Bedogni MD Antonio Colombo MD 《Catheterization and cardiovascular interventions》2015,86(7):1168-1176
20.
Complex patients treated with zotarolimus‐eluting resolute and everolimus‐eluting xience V stents in the randomized TWENTE trial: Comparison of 2‐year clinical outcome 下载免费PDF全文
Hanim Sen Ming Kai Lam Kenneth Tandjung Marije M. Lwik Martin G. Stoel Frits H.A.F. de Man J. W. Louwerenburg Gert K. van Houwelingen Gerard C.M. Linssen Carine J.M. Doggen Mounir W.Z. Basalus Clemens von Birgelen 《Catheterization and cardiovascular interventions》2015,85(1):74-81